Papadakos Stavros P, Dedes Nikolaos, Kouroumalis Elias, Theocharis Stamatios
First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Department of Gastroenterology, Medical School, University of Crete, 71500 Heraklion, Greece.
Cancers (Basel). 2022 Jun 27;14(13):3150. doi: 10.3390/cancers14133150.
The HCC constitutes one of the most frequent cancers, with a non-decreasing trend in disease mortality despite advances in systemic therapy and surgery. This trend is fueled by the rise of an obesity wave which is prominent the Western populations and has reshaped the etiologic landscape of HCC. Interest in the nucleotide-binding domain leucine-rich repeat containing (NLR) family member NLRP3 has recently been revived since it would appear that, by generating inflammasomes, it participates in several physiologic processes and its dysfunction leads to disease. The NLRP3 inflammasome has been studied in depth, and its influence in HCC pathogenesis has been extensively documented during the past quinquennial. Since inflammation comprises a major regulator of carcinogenesis, it is of paramount importance an attempt to evaluate the contribution of the NLRP3 inflammasome to the generation and management of HCC. The aim of this review was to examine the literature in order to determine the impact of the NLRP3 inflammasome on, and present a hypothesis about its input in, HCC.
肝细胞癌(HCC)是最常见的癌症之一,尽管在全身治疗和手术方面取得了进展,但疾病死亡率仍呈上升趋势。肥胖浪潮的兴起加剧了这一趋势,肥胖在西方人群中尤为突出,并重塑了HCC的病因格局。最近,人们对含核苷酸结合域富含亮氨酸重复序列(NLR)的家族成员NLRP3的兴趣再度燃起,因为它似乎通过生成炎性小体参与多种生理过程,其功能障碍会导致疾病。NLRP3炎性小体已得到深入研究,在过去五年中,其对HCC发病机制的影响已有大量文献记载。由于炎症是致癌作用的主要调节因素,因此评估NLRP3炎性小体对HCC发生和治疗的贡献至关重要。本综述的目的是查阅文献,以确定NLRP3炎性小体对HCC的影响,并提出关于其在HCC中作用的假说。
Cancers (Basel). 2022-6-27
Front Immunol. 2021
Arterioscler Thromb Vasc Biol. 2018-12
Acta Ophthalmol. 2017-12
Trends Biochem Sci. 2016-12
Front Pharmacol. 2024-7-31
Cancers (Basel). 2024-7-22
Int J Mol Sci. 2024-1-23
Cancers (Basel). 2023-7-26
Front Immunol. 2022
Int J Mol Sci. 2022-4-11
Int J Mol Sci. 2022-4-7
Pathogens. 2022-4-14
Liver Int. 2023-8
Clin Transl Oncol. 2022-8